Tang Capital Management’s Tango Therapeutics TNGX Stock Holding History

Tang Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-200,000	Closed	-$1.98M	–	131
2023 Q4	$1.98M	Hold	200,000	–	–	0.18%	92
2023 Q3	$2.25M	Hold	200,000	–	–	0.32%	68
2023 Q2	$664K	Hold	200,000	–	–	0.1%	86
2023 Q1	$790K	Buy	+200,000	New	+$1.16M	0.12%	82
2022 Q3	–	Sell	-468,750	Closed	-$2.12M	–	99
2022 Q2	$2.12M	Hold	468,750	–	–	0.32%	49
2022 Q1	$3.55M	Hold	468,750	–	–	0.71%	35
2021 Q4	$5.13M	Hold	468,750	–	–	1.03%	23
2021 Q3	$6.06M	Hold	468,750	–	–	1.26%	15
2021 Q2	$5.33M	Hold	468,750	–	–	1.06%	13
2021 Q1	$5.21M	Hold	468,750	–	–	1.47%	9
2020 Q4	$5.36M	Hold	468,750	–	–	0.82%	9
2020 Q3	$4.86M	Buy	+468,750	New	+$4.79M	0.88%	15

Other funds holding TNGX

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Tang Capital Management's TNGX Position: Q1 2024 in Review

Tang Capital Management sold out of Tango Therapeutics (TNGX) in Q1 2024, closing a stake of 200,000 shares — an estimated $1.98M sold.

Tang Capital Management first reported a position in TNGX in Q3 2020 and held it in 12 quarters. The position peaked at $6.06M in Q3 2021. 126 funds tracked by Wall St. Rank hold TNGX as of Q1 2024.

Tang Capital Management reported no remaining Tango Therapeutics position as of Q1 2024 after selling out during the quarter.
Tang Capital Management sold 200,000 Tango Therapeutics shares in Q1 2024, an estimated $1.98M.
Tang Capital Management first reported a position in Tango Therapeutics in Q3 2020 and held it in 12 quarters.
Tang Capital Management's Tango Therapeutics position peaked at $6.06M in Q3 2021.
126 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.